Marijuana Inc. Stock Price, News & Analysis

Exousia Pro (OTCPINK:MAJI), a clinical-stage biotechnology company, reported positive developments in its legal proceedings against former CEO Donald Steinberg and related shareholders. The company secured a standstill order on approximately 10.5% of outstanding shares held by the former CEO.

Additionally, Exousia Pro executed two rescission agreements blocking legend removal on 3,250,000 shares (approximately 8% of outstanding shares). While the Temporary Restraining Order hearing was not conducted, the company achieved significant shareholder protections through these legal measures.

The company plans to refocus on its core business of developing exosome-based cancer therapies and will provide updates on ongoing studies, therapies, and patents.

Exousia Pro (OTCPINK:MAJI) has filed a provisional patent (#63/877,517) for a novel method of loading Extracellular Vesicles (EVs), marking a significant strategic advancement in exosome-based therapies. The technology, to be utilized under the Exousia Health division, enhances the efficiency and stability of therapeutic agent delivery through exosomes.

The innovation targets three major markets with a combined value exceeding $2.7 trillion: the pharmaceutical market ($1.77 trillion), nutraceuticals market ($500 billion), and cosmetics market ($450 billion). The company is preparing to file trademarks for new products leveraging this technology, representing one of two patent-ready technologies currently in development.

Exousia Pro (OTCPINK:MAJI) announced its strategic entry into the telehealth market through an acquisition that will establish its new division, Exousia Health. The acquired telehealth company brings an initial base of 1,000 active clients and projected monthly revenue of $50,000.

The company is reviewing two additional significant contracts expected to boost monthly revenue substantially. Exousia Health also plans to integrate a compounding pharmacy operation, creating a third revenue stream by handling prescriptions from its telehealth doctors directly.

Management expects Exousia Health to become the company's primary revenue generator until its AI division begins licensing cancer therapy technology.

Exousia Pro (OTCPINK:MAJI), a clinical-stage biotech company, has announced the creation of three new divisions under a newly formed subsidiary, Exousia Pro Holding Management, LLC (EPHM). The divisions include Exousia Ai, Exousia Health, and Exousia Wholesale, each structured for independent growth and potential future spin-offs.

The company plans to file two new patents in September 2025 and is developing new products for a market currently valued at $8.7 billion, expected to reach $18.5 billion in the next decade. Exousia Health is preparing to enter a partnership giving access to 200,000 active patients for marketing subscription-based health products.

Exousia Pro (OTCPINK:MAJI), a clinical-stage biotech company, has filed a Regulation A offering to raise up to $4.985 million for various business initiatives. The company plans to allocate the funds across several key areas, with the largest portion ($2 million) dedicated to Investigational New Drug (IND) trials for Glioblastoma treatment.

The funding will also support new product development from mushroom exosomes ($1 million), potential acquisitions ($1.5 million), lab equipment ($250,000), marketing ($150,000), and working capital ($85,000). The company emphasizes a strategic approach to raising capital, planning to secure funds as needed to avoid excessive shareholder dilution.

Exousia Pro (OTCPINK:MAJI), a clinical-stage biotech company focused on exosome therapies for cancer and other diseases, has announced the expansion of its Scientific Advisory Board (SAB) with Dr. Marvin S. Hausman, MD as Chairman. The newly assembled SAB includes distinguished experts: Dr. Robert B. Beelman (Professor Emeritus of Food Science at Penn State), Dr. Kyle H. Ambert (Director of Data Science at Nike), Dr. Zachary T. Bitzer (Assistant Professor at Penn State), and Dr. Anthony Smith (natural product development expert). Dr. Hausman brings over 40 years of drug research experience and has served in leadership roles at companies like Bristol Myers International and Ludwig Enterprises. The advisory board will guide Exousia Pro's expansion into new areas with plant-based exosomes.

Exousia Pro announces the addition of Dr. Marvin Hausman as a consultant and the launch of a new weekly web series titled "Ask Dr. Hausman." The clinical-stage biotech company, trading as MAJI on OTCPINK, focuses on developing exosome-based therapies for cancer and other diseases.

Dr. Hausman, who played a key role in creating Exousia AI and establishing the Glioblastoma study with UCF, will host the series where shareholders can submit questions. The program will cover updates on ongoing studies, FDA submissions, and future IND trials.

Company President Matt Dwyer highlighted Dr. Hausman's valuable network of scientific and financial professionals in the biotech sector, expressing confidence that this collaboration will open new opportunities for Exousia Pro's advancement in plant-based exosome therapies.

Exousia Pro has completed its preclinical trial for glioblastoma treatment ahead of schedule, strengthening its FDA Orphan Drug Application. The company employed an advanced humanized mouse model using actual human glioblastoma tumor cells, setting it apart from 90% of typical preclinical studies.

The trial involved 32 mice divided into four groups testing different treatment combinations: control, temozolomide (TMZ) alone, exosome treatment alone, and TMZ-exosome combination therapy. The 14-day tumor establishment period was followed by a seven-day treatment phase.

CEO Mike Sheikh highlighted that their unique exosomal-based therapy approach allows for targeted treatment through a singular process where cells perform the loading work. Earlier in vitro studies showed promising results when combining their exosome therapy with minimal chemotherapy, particularly in eliminating cancer stem cells - a major obstacle in glioblastoma treatment.

The company expects to receive comprehensive trial results by mid-to-late May 2025, which will support their FDA Orphan Drug Application.

Exousia Pro (OTC PINK:MAJI) has shared significant findings regarding their Glioblastoma (GBM) study. Chief Science Officer Dr. Marvin Hausman revealed in a Spaces interview that published research demonstrates the effectiveness of NANOG Expression therapy in treating GBM cells.

The research showed that while temozolomide (TMZ) alone at maximum concentration eliminated less than 20% of GBM cells, combining TMZ with shRNA targeting NANOG or OCT4 significantly increased cell death rates. This combination therapy proved particularly effective at reducing the resistance of Cancer stem cells in Glioblastoma.